Bafna Pharmaceuticals Ltd., a Rs. 120 crore Chennai-based pharma company engaged in manufacturing of pharmaceutical formulations of betalactum and non-betalactum, has received approval from Ghana Food and Drug Administration (FDA) to market Omeran-20 capsules (gastro-resistant omerprazole capsules 20mg).

The capsules are proton pump inhibitors used in the treatment of reflux oesophagitis, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and zollinger-ellison syndrome.

The drug contains generic salt - omeprazole - and its International classification of diseases is omeprazole. With this, Bafna now has 15 number of formulation approvals from Ghana FDA.

Mahaveer Bafna, CMD, Bafna Pharmaceuticals Ltd said, “This approval is a major milestone for Bafna Pharmaceuticals. It will strengthen our market in Ghana and help us in penetrating in our target market segment. We have already received product approval from Ghana FDA in the past nad with the entry of omeran, it has added a new feather in the cap.”

Bafna is already present in Ghana with the FDA approvals including: Atenolol 50mg and Atenol 100mg tablets, metformin tablets BP 500mg, Fluconazole tablets 150mg, iron tonic fortified with protein, folic acid, vitamin B12 and zinc syrup, haematinic capsules and vitamins and zinc, azithromycin tablets 250mg, azithromycin tablets 500mg, amlodipine besilate tablets 5mg and amlodipine besilate tablets 10mg, diclofenac sodium, paracetamol and chlorzoxazone tablets, Glibenclamide tablets 5mg, azithromycin suspension, iron with folic acid capsules.